Vanda Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.12.24	Vanda Pharma's VGT-1849A Gets Orphan Drug Designation From FDA (RTTNews)
14.10.24	Vanda Pharma Gets Second Unsolicited Acquisition Offer From Cycle Group (RTTNews)
19.09.24	Why Is Vanda Pharmaceuticals Stock Falling In Pre-market? (RTTNews)
02.09.24	Biotech Stocks Facing FDA Decision In September 2024 (RTTNews)
20.06.24	Vanda Rejects Takeover Proposals From Cycle Group, Future Pak (RTTNews)
13.06.24	Vanda Receives Revised Takeover Proposal From Future Pak; Stock Up (RTTNews)
06.06.24	Vanda Pharmaceuticals Receives Unsolicited, Non-binding $8.00/share Cash Offer From Cycle Group (RTTNews)
15.05.24	Vanda Pharma Reports Positive Results From Second Phase III Study Of Tradipitant (RTTNews)
07.05.24	Vanda Pharma Receives Revised Unsolicited Takeover Proposal From Future Pak (RTTNews)
23.04.24	Supreme Court Denies Vanda Pharma' Petition In HETLIOZ Litigation Against Teva, Apotex (RTTNews)
17.04.24	Vanda Pharma Adopts Limited Duration Stockholder Rights Plan; Stock Up (RTTNews)
17.04.24	Vanda Pharma Rejects Future Pak's Takeover Proposals; Stock Climbs (RTTNews)
17.04.24	Future Pak Confirms Offer To Buy Vanda For $7.25 - $7.75 Per Share In Cash; VNDA Up Over 28% (RTTNews)
03.04.24	Vanda's Fanapt Gets FDA Approval For Acute Treatment Of Bipolar I Disorder; Stock Up In After-hours (RTTNews)
28.03.24	Biotech Stocks Facing FDA Decision In April 2024 (RTTNews)
06.03.24	Vanda Pharmaceuticals Receives CRL From FDA On SNDA For HETLIOZ - Quick Facts (RTTNews)
28.02.24	Biotech Stocks Facing FDA Decision In March 2024 (RTTNews)
05.02.24	Vanda Pharmaceuticals: FDA Identifies Deficiencies In Connection With SNDA For HETLIOZ (RTTNews)
31.01.24	Vanda Pharma's IND For VTR-297 Gets FDA Approval To Treat Onychomycosis (RTTNews)
30.01.24	U.S. Court Orders FDA To Resolve Vanda Pharma' Jet Lag Hearing Request By March 5 (RTTNews)
26.01.24	Vanda Pharma Announces U.S. Patent Allowance For PONVORY (RTTNews)
23.01.24	Vanda Pharma's IND Application To Evaluate VCA-894A Approved By FDA (RTTNews)
07.12.23	Vanda Pharmaceuticals Acquires U.S., Canadian Rights To PONVORY From Janssen (RTTNews)
07.12.23	Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis (PR Newswire)
05.12.23	Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis (PR Newswire)
09.11.23	Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences (PR Newswire)
08.11.23	Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results (PR Newswire)
01.11.23	Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023 (PR Newswire)
20.10.23	Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation (PR Newswire)
06.10.23	Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit (PR Newswire)
06.09.23	Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference (PR Newswire)
02.09.23	Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
27.07.23	Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results (PR Newswire)
20.07.23	Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023 (PR Newswire)
05.06.23	Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference (PR Newswire)
02.06.23	Vanda Pharmaceuticals Announces Presentations at SLEEP 2023 (PR Newswire)
02.06.23	Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S (PR Newswire)
25.05.23	Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness (PR Newswire)
10.05.23	Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal (PR Newswire)
05.05.23	Vanda Pharmaceuticals Announces Presentations at DDW 2023 (PR Newswire)
02.05.23	Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information (PR Newswire)
28.04.23	Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023 (PR Newswire)
28.03.23	Vanda Prevails in Jet Lag Litigation Against the FDA (PR Newswire)
17.03.23	Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors (PR Newswire)
08.02.23	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire)
02.02.23	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023 (PR Newswire)
06.01.23	Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference (PR Newswire)
19.12.22	Vanda Pharma: Phase III Study Shows Potential Of Fanapt In Treating Bipolar I Disorder (RTTNews)
19.12.22	Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study (PR Newswire)
16.12.22	Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Vanda Pharmaceuticals IncShs

Aktien Top/Flop

Vanda Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten